ARTICLES BY CINDY DUBIN

  • 13_Iovance_1017_450x300
    A Name Change — And More — For A Biotech
    10/10/2017

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

Cindy Dubin

Cindy Dubin

Cindy Dubin has been reporting on the pharmaceutical industry since 2003, with a particular focus on executive decision making regarding formulation, delivery, development, and commercialization. She is the former Editor-in-Chief of both Pharmaceutical Formulation & Quality and Specialty Pharma magazines. She is now a freelance writer.